Bioneer Corporation announced that it has received KRW 5 billion in funding from LB Investment Inc., KDB Capital Corporation, Investment Arm, IBK Capital Corporation, Anda Investment Partners, and another investor.
April 03, 2014 at 12:00 am
Share
Bioneer Corporation (KOSDAQ:A064550) announced that it will receive KRW 5,000,000,000 in funding on April 1, 2014. The company will issue its sixth domestic unregistered unsecured private convertible bonds in the transaction. The bonds will be subscribed by Future Creation LB Leading Company Investment Fund No. 20, a fund managed by LB Investment Inc., KDBC Biomedical New Growth Investment Fund, a fund managed by KDB Capital Corp., IBK Financial Group Shared Growth PEF, a fund managed by IBK Capital Corporation, Anda Investment Partners, and an existing shareholder of the company, Sung-Jin Hwang. The bonds will mature on April 3, 2017 and will not carry any coupon rate. The yield to maturity will be 7%. The bonds are 100% convertible into common shares of the company at a conversion price of KRW 16,000 per share during the conversion period from April 3, 2015 to March 3, 2017. Future Creation LB Leading Company Investment Fund No. 20, KDBC Biomedical New Growth Investment Fund, IBK Financial Group Shared Growth PEF, Anda Investment Partners, and Sung-Jin Hwang will subscribe to the bonds for proceeds of KRW 1,500,000,000, KRW 1,000,000,000, KRW 1,000,000,000, KRW 1,000,000,000, and KRW 500,000,000 respectively. Payment date for the transaction is April 3, 2014. The transaction was approved by the board of directors of the company.
On April 3, 2014, Bioneer Corporation closed the transaction.
BIONEER CORPORATION is a Korea-based company engaged in the biotechnology business. The Company mainly focuses on the development of deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits and other services, such as DNA and ribonucleic acid (RNA) amplification products, Oligo synthesis and reagents, gene synthesis services, gene expressions, protein expressions and purifications, genomics services, human diagnostics kits, veterinary diagnostics kits and others. It also provides DNA devices, including DNA extraction, amplification and quantitative analysis devices and other DNA diagnostic devices, and supplies for tests and others. In addition, it provides equipment and supplies used for biotechnology research. The Company operates its business within domestic market and in overseas markets, including America, China, Japan, India, Africa and others.
Bioneer Corporation announced that it has received KRW 5 billion in funding from LB Investment Inc., KDB Capital Corporation, Investment Arm, IBK Capital Corporation, Anda Investment Partners, and another investor.
BIONEER CORPORATION 